Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
Young African-American women with breast cancer report more symptoms of depression than their healthy peers, even when they have good social support systems and an ability to adapt to new environments or situations, a study published in the Journal of Cancer Survivorship shows.
Women with HER2-positive metastatic breast cancer who experience growth or worsening of the disease after treatment with other anti-HER2 therapies can expect a significant progression-free survival benefit from the recently FDA approved antibody-drug conjugate T-DM1 (Kadcyla), first results from the phase III TH3RESA trial show. The findings were presented at the 2013 European Cancer Congress (ECC) in Amsterdam on September 28.
(Reuters) - Quest Diagnostics Inc on Tuesday became the largest U.S. company to start offering gene-based tests for inherited forms of breast cancer since the U.S. Supreme Court ended Myriad Genetics Inc's monopoly on the tests for specific gene mutations.
A study published in Psycho-Oncology suggests that the way a couple communicates about cancer-related concerns plays a role in worsening or improving symptoms of depression related to problems with sex and physical intimacy in women living with metastatic disease.
A German study published in The Annals of Thoracic Surgery suggests that surgical removal of breast cancer metastases that affect a small part of the lungs may help women live longer.
Women with metastatic breast cancer may have no growth or spread of cancer for longer spans of time if they continue chemotherapy even after the disease is under control, a recent study found.
Genentech, a developer of medicine, announced September 30 that the U.S. Food and Drug Administration granted accelerated approval of the company’s medicine pertuzumab (Perjeta)—in combination with trastuzumab (Herceptin) and docetaxel—as pre-surgery treatment for those with high-risk, HER2-positive, inflammatory, early-stage or locally advanced breast cancer.
A study of women with estrogen receptor-positive, invasive breast cancer showed that while most women start and complete treatment with hormonal therapy as prescribed, certain groups are more likely than others to stop taking it before the recommended date, or to never take it at all.
Postmenopausal women with metastatic, hormone receptor-positive breast cancer who are treated with everolimus (Afinitor) plus exemestane (Aromasin) experience delays in cancer progression while maintaining the same quality of life they would have if treated with exemestane alone, a secondary analysis of the BOLERO-2 trial found.
Mindfulness practice has a moderate to large positive impact on improving the mental health of women affected by breast cancer, a recent analysis of nine studies suggests.